Factors associated with dental abnormalities and other damage
| Variable . | IRR (95% CI) . | P . |
|---|---|---|
| Viral infection prior transplantation | 1.0 (0.3-3.7) | 1.0 |
| Ulcers | 3.2 (0.7-14.0) | .1 |
| Age in mo at diagnosis (≥3 mo) | 2.0 (0.5-7.6) | .3 |
| High busulfan dose (vs low) | 5.3 (0.6-50.1) | .1 |
| Myeloablative conditioning | 2.3 (0.6-8.1) | .2 |
| Any alkylator therapy | 14.2 (2.7-76.1) | .002 |
| Haploidentical donor | 3.3 (0.8-14.0) | .1 |
| No myeloid chimerism (recipient) | 0.3 (0.1-1.0) | .04 |
| Retransplantation | 0.4 (0.1-2.3) | .3 |
| Boost | 0.2 (0.0-0.9) | .03 |
| Additional procedure | 0.3 (0.1-1.0) | .05 |
| IVIG requirement | 0.3 (0.1-1.1) | .07 |
| CD4+ T cells at 2 y post-HCT (≤600 cells/mm3) | 0.4 (0.1-1.4) | .2 |
| Variable . | IRR (95% CI) . | P . |
|---|---|---|
| Viral infection prior transplantation | 1.0 (0.3-3.7) | 1.0 |
| Ulcers | 3.2 (0.7-14.0) | .1 |
| Age in mo at diagnosis (≥3 mo) | 2.0 (0.5-7.6) | .3 |
| High busulfan dose (vs low) | 5.3 (0.6-50.1) | .1 |
| Myeloablative conditioning | 2.3 (0.6-8.1) | .2 |
| Any alkylator therapy | 14.2 (2.7-76.1) | .002 |
| Haploidentical donor | 3.3 (0.8-14.0) | .1 |
| No myeloid chimerism (recipient) | 0.3 (0.1-1.0) | .04 |
| Retransplantation | 0.4 (0.1-2.3) | .3 |
| Boost | 0.2 (0.0-0.9) | .03 |
| Additional procedure | 0.3 (0.1-1.0) | .05 |
| IVIG requirement | 0.3 (0.1-1.1) | .07 |
| CD4+ T cells at 2 y post-HCT (≤600 cells/mm3) | 0.4 (0.1-1.4) | .2 |
The analysis was performed in ARTEMIS patients only because all events happened in these patients, and this situation made the model in the whole population not converging. The procedure xtmepoisson Stata was used to model data to count the number of events over time. Patients were clustered using a group variable to take into account the practice variations between centers. No multivariate modeling was possible because of too few patients included (n = 47).
IRR, incidence rate of ratio.